PortalPublikationenSevere meningo-/encephalitis after daclizumab therapy for mu...

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis

Standard

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. / Stork, Lidia; Brück, Wolfgang; von Gottberg, Phillip; Pulkowski, Ulrich; Kirsten, Florian; Glatzel, Markus; Rauer, Sebastian; Scheibe, Franziska; Radbruch, Helena; Hammer, Eckhard; Stürner, Klarissa H; Kaulen, Barbara; Heesen, Christoph; Hoffmann, Frank; Brock, Sebastian; Pawlitzki, Marc; Bopp, Tobias; Metz, Imke.

in: MULT SCLER J, Jahrgang 25, Nr. 12, 10.2019, S. 1618-1632.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stork, L, Brück, W, von Gottberg, P, Pulkowski, U, Kirsten, F, Glatzel, M, Rauer, S, Scheibe, F, Radbruch, H, Hammer, E, Stürner, KH, Kaulen, B, Heesen, C, Hoffmann, F, Brock, S, Pawlitzki, M, Bopp, T & Metz, I 2019, 'Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis', MULT SCLER J, Jg. 25, Nr. 12, S. 1618-1632. https://doi.org/10.1177/1352458518819098

APA

Stork, L., Brück, W., von Gottberg, P., Pulkowski, U., Kirsten, F., Glatzel, M., Rauer, S., Scheibe, F., Radbruch, H., Hammer, E., Stürner, K. H., Kaulen, B., Heesen, C., Hoffmann, F., Brock, S., Pawlitzki, M., Bopp, T., & Metz, I. (2019). Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. MULT SCLER J, 25(12), 1618-1632. https://doi.org/10.1177/1352458518819098

Vancouver

Stork L, Brück W, von Gottberg P, Pulkowski U, Kirsten F, Glatzel M et al. Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis. MULT SCLER J. 2019 Okt;25(12):1618-1632. https://doi.org/10.1177/1352458518819098

Bibtex

@article{78f245f4edf543a88ee83583f4007a2d,
title = "Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis",
abstract = "BACKGROUND:: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018.OBJECTIVE AND METHODS:: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy.RESULTS:: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis revealed an increase in eosinophils (5/7). Six patients fulfilled the diagnostic criteria for a drug reaction with eosinophilia and systemic symptoms (DRESS). Magnetic resonance imaging (MRI) showed multiple contrast-enhancing lesions, and enhancement of the ependyma (6/7), meninges (5/7), cranial or spinal nerves (2/7), and a vasculitic pattern (3/7). Histology revealed a pronounced inflammatory infiltrate consisting of lymphocytes, plasma cells and eosinophils, and densely infiltrated vessels. Most patients showed an insufficient therapeutic response and a high disability at last follow-up (median Expanded Disability Status Scale (EDSS) 8). Two patients died.CONCLUSION:: Meningoencephalitis and DRESS may occur with daclizumab therapy. This potential lethal side effect is characterized by a dysregulated immune response. Our findings underline the importance of postmarketing drug surveillance.",
keywords = "Journal Article",
author = "Lidia Stork and Wolfgang Br{\"u}ck and {von Gottberg}, Phillip and Ulrich Pulkowski and Florian Kirsten and Markus Glatzel and Sebastian Rauer and Franziska Scheibe and Helena Radbruch and Eckhard Hammer and St{\"u}rner, {Klarissa H} and Barbara Kaulen and Christoph Heesen and Frank Hoffmann and Sebastian Brock and Marc Pawlitzki and Tobias Bopp and Imke Metz",
year = "2019",
month = oct,
doi = "10.1177/1352458518819098",
language = "English",
volume = "25",
pages = "1618--1632",
journal = "MULT SCLER J",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "12",

}

RIS

TY - JOUR

T1 - Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis

AU - Stork, Lidia

AU - Brück, Wolfgang

AU - von Gottberg, Phillip

AU - Pulkowski, Ulrich

AU - Kirsten, Florian

AU - Glatzel, Markus

AU - Rauer, Sebastian

AU - Scheibe, Franziska

AU - Radbruch, Helena

AU - Hammer, Eckhard

AU - Stürner, Klarissa H

AU - Kaulen, Barbara

AU - Heesen, Christoph

AU - Hoffmann, Frank

AU - Brock, Sebastian

AU - Pawlitzki, Marc

AU - Bopp, Tobias

AU - Metz, Imke

PY - 2019/10

Y1 - 2019/10

N2 - BACKGROUND:: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018.OBJECTIVE AND METHODS:: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy.RESULTS:: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis revealed an increase in eosinophils (5/7). Six patients fulfilled the diagnostic criteria for a drug reaction with eosinophilia and systemic symptoms (DRESS). Magnetic resonance imaging (MRI) showed multiple contrast-enhancing lesions, and enhancement of the ependyma (6/7), meninges (5/7), cranial or spinal nerves (2/7), and a vasculitic pattern (3/7). Histology revealed a pronounced inflammatory infiltrate consisting of lymphocytes, plasma cells and eosinophils, and densely infiltrated vessels. Most patients showed an insufficient therapeutic response and a high disability at last follow-up (median Expanded Disability Status Scale (EDSS) 8). Two patients died.CONCLUSION:: Meningoencephalitis and DRESS may occur with daclizumab therapy. This potential lethal side effect is characterized by a dysregulated immune response. Our findings underline the importance of postmarketing drug surveillance.

AB - BACKGROUND:: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018.OBJECTIVE AND METHODS:: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy.RESULTS:: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis revealed an increase in eosinophils (5/7). Six patients fulfilled the diagnostic criteria for a drug reaction with eosinophilia and systemic symptoms (DRESS). Magnetic resonance imaging (MRI) showed multiple contrast-enhancing lesions, and enhancement of the ependyma (6/7), meninges (5/7), cranial or spinal nerves (2/7), and a vasculitic pattern (3/7). Histology revealed a pronounced inflammatory infiltrate consisting of lymphocytes, plasma cells and eosinophils, and densely infiltrated vessels. Most patients showed an insufficient therapeutic response and a high disability at last follow-up (median Expanded Disability Status Scale (EDSS) 8). Two patients died.CONCLUSION:: Meningoencephalitis and DRESS may occur with daclizumab therapy. This potential lethal side effect is characterized by a dysregulated immune response. Our findings underline the importance of postmarketing drug surveillance.

KW - Journal Article

U2 - 10.1177/1352458518819098

DO - 10.1177/1352458518819098

M3 - SCORING: Journal article

C2 - 30657420

VL - 25

SP - 1618

EP - 1632

JO - MULT SCLER J

JF - MULT SCLER J

SN - 1352-4585

IS - 12

ER -